Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

SOUTH SAN FRANCISCO, Calif. , Feb. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…

Continue ReadingAllogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif. , Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics ,…

Continue ReadingAllogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma SOUTH SAN FRANCISCO, Calif. , Jan. 24, 2023 (GLOBE NEWSWIRE)…

Continue ReadingAllogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2023 (GLOBE…

Continue ReadingAllogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in Relapsed/Refractory (R/R) Large B Cell…

Continue ReadingAllogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

Promising Preclinical Data Highlights a Simple One-Step Gene Editing Strategy to Prevent the Rejection of AlloCAR T™ Cells by Host T Cells and NK Cells Cloaking Approach Demonstrates Superiority to B2M…

Continue ReadingAllogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…

Continue ReadingAllogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology

ALLO-715, an Allogeneic BCMA CAR T Candidate Dosed with an ALLO-647 Based Lymphodepletion Regimen, Continues to Demonstrate a Promising Clinical Profile A Company Sponsored R&D Showcase on November 29, 2022…

Continue ReadingAllogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology